Five things for pharma marketers to know: Monday, November 6, 2017

Share this content:


1. Valeant Pharmaceuticals International will sell female libido drug Addyi back to former owner Sprout Pharmaceuticals. Valeant acquired Sprout and Addyi in 2015 for $1 billion. (Reuters)

2. Some advertisers have halted business with Outcome Health following allegations that the point-of-care company inflated numbers in their campaigns. Bristol-Myers Squibb did not renew its business with the company and Omnicom Group has suspended advertising until the company conducts a third-party audit. (WSJ)  

3. The Trump Administration has drafted an executive order that would repeal Obamacare's individual mandate, but has held the order to see if lawmakers can include a repeal in the upcoming tax-reform bill, according to an unnamed U.S. senator. (Washington Examiner)

4. Amgen plans to eliminate 200 R&D positions by the end of the year. The eliminated positions are based in its Thousand Oaks, California, and South San Francisco offices. (STAT)

5. Cardinal Health said CEO George Barrett will step down from the role next year. The company CFO Mike Kaufmann will become the new CEO. (WSJ)

Share this content:
Scroll down to see the next article